-transparent.png){kind=logo}
A batch of lyophilised human diploid-cell-strain rabies vaccine was divided into three batches, which were exposed to different temperatures during their distribution to and storage at three centres in Pakistan. Vaccine potency after exposure to these temperatures was tested by measuring antibody response in those given the vaccine, and by three different laboratory tests. The results indicate that the vaccine retains its antigenicity for man and for laboratory tests despite continuous exposure to high ambient temperatures for up to 11 weeks. These findings, together with current developments in vaccine manufacture and treatment schedules, offer considerable hope to many countries with low budgets for health care and where rabies is poorly controlled.
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
August 1980,
The Journal of infectious diseases,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
October 1980,
The Medical letter on drugs and therapeutics,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
June 1977,
The Veterinary record,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
March 1985,
The Journal of communicable diseases,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
June 1983,
Lancet (London, England),
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
March 1984,
Journal of the American Veterinary Medical Association,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
February 1985,
Lancet (London, England),
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
July 1978,
Journal of biological standardization,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
January 1976,
Developments in biological standardization,
K G Nicholson, and
M I Burney, and
S Ali, and
F T Perkins
January 1978,
Developments in biological standardization,
